Page results
-
UCLH has continued to achieve excellent results in the National Inpatient Survey, with patients rating their overall care as 8.7 out of 10 – the top score amongst our London peers.
-
A world-first treatment for Creutzfeldt-Jakob disease (CJD) has shown “very encouraging” early results following its use in six patients at University College London Hospitals (UCLH) NHS Foundation Trust.
-
Mr George Attilakos is a consultant in obstetrics and fetal medicine and the clinical lead for obstetrics at UCLH. Alongside managing normal pregnancies, Mr Attilakos has a special interest in the management of multiple pregnancies and high-risk pregnancies, as well as expertise in fetal medicine and fetal surgery, including in-utero treatment for congenital diaphragmatic hernia, spina bifida and twin-to-twin transfusion syndrome.
-
Read more about the Halcyon linear accelerator, aimed at making cancer treatment faster, more comfortable, and more precise for patients.
-
The Neurorehabilitation Unit (NRU) at The National Hospital for Neurology and Neurosurgery (NHNN) has been refurbished with funding from The National Brain Appeal to provide new facilities and additional space, transforming it into a more therapeutic environment.
-
You now need a registered site administrator to access EpicCare Link UCLH for your practice or service. If your site doesn’t have a registered administrator, you may lose access to EpicCare Link UCLH.
-
Information about the new government support available to help people pay their energy bills.
-
When Sam Ahern was born 24 years ago, she was the smallest baby our neonatal unit had ever looked after. Now an accomplished musician and fine art student, she has gone back to meet the team that helped her win her fight for life.
-
A new toolkit to support babies, children and young people in healthcare access high quality health play services was launched at UCLH last week with UCLH chief nurse Vanessa Sweeney welcoming visitors from NHS England and the play charity Starlight.
-
A new CAR T-cell therapy developed by scientists at UCL has fewer ‘toxic’ side-effects and is more durable, targeting and killing cancer cells for longer, concludes a Phase 1 clinical trial of patients at UCLH.